TIDMDDDD

RNS Number : 5561R

4d Pharma PLC

30 June 2020

4D pharma plc

(the "Company" or "4D")

Result of AGM

At the annual general meeting of 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, held earlier today, all resolutions put to shareholders were duly passed.

The full text of each resolution was included in the notice of the meeting, which was posted to shareholders on 5 June 2020, and is available on the Company's website www.4dpharmaplc.com .

The proxy votes for the resolutions will shortly be available on the Company's website.

For further information please contact:

4D

   Duncan Peyton, Chief Executive Officer                                         +44 (0)113 895 0130

Investor Relations ir@4dpharmaplc.com

   N+1 Singer - Nominated Adviser and Joint Broker                    +44 (0)20 7496 3000

Aubrey Powell / Justin McKeegan / Iqra Amin (Corporate Finance)

Tom Salvesen (Corporate Broking)

   Bryan Garnier & Co. Limited - Joint Broker                                +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

Image Box PR

Neil Hunter / Michelle Boxall +44 (0)20 8943 4685

About 4D pharma plc

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx (R) , that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D's Live Biotherapeutic Products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical studies in progress, namely a Phase II clinical study of BLAUTIX (R) in Irritable Bowel Syndrome (IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer and a Phase I/II study of MRx-4DP0004 in asthma. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGZZGFVMGDGGZM

(END) Dow Jones Newswires

June 30, 2020 08:05 ET (12:05 GMT)

4d Pharma (LSE:DDDD)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas 4d Pharma.
4d Pharma (LSE:DDDD)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas 4d Pharma.